证券代码：300255 证券简称：常山药业 公告编号：2023-51 河北常山生化药业股份有限公司 股票交易异常波动公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 河北常山生化药业股份有限公司（以下简称"公司"）股票连续两个交易日（2023 年 9 月 11 日、2023 年 9 月 12 日）收盘价格涨幅偏离值累计超过 30%，根据深圳证 券交易所的相关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况的说明 针对公司股票交易异常波动情况，公司对相关事项进行了核实，现就相关情况 说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3、公司近期经营情况正常，主营业务未发生变化，内外部经营环境未发生重大 变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而未披露 的重大事项，也不存在处于筹划阶段的重大事项； 5、经核查，公司控股股东、实际控制人在公司股票交易异常波动期间不存在买 卖公司股票 ...

证券代码：300255 证券简称：常山药业 公告编号：2023-50 河北常山生化药业股份有限公司 关于召开 2023 年第二次临时股东大会通知的更正公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 同一股份只能选择现场投票、网络投票或符合规定的其他投票方式中的一种 表决方式。同一表决权出现重复表决的以第二次投票结果为准。 更正后： （五）会议的召开方式 …… 同一股份只能选择现场投票、网络投票或符合规定的其他投票方式中的一种 表决方式。同一表决权出现重复表决的以第一次投票结果为准。 附件 1：参加网络投票具体操作流程 更正前： 河北常山生化药业股份有限公司（以下简称"公司"）于 2023 年 8 月 31 日 在巨潮资讯网（www.cninfo.com.cn）上披露了《关于召开 2023 年第二次临时股 东大会通知的公告》（公告编号：2023-49）。（以下简称"原公告"）。经审查，原 公告中同一表决权重复表决情况的计票规则有误。现对公告中部分内容更正如下： 一、召开会议的基本情况 更正前： （五）会议的召开方式 …… 一、网络投票的程序 4.股东对总议 ...

Financial Performance - In the first half of 2023, the company achieved operating revenue of CNY 820.375 million, a decrease of 28.45% compared to the same period last year[32]. - The net profit attributable to shareholders was CNY -155.8783 million, a decline of 340.70% year-on-year[32]. - The company reported a basic earnings per share of -¥0.17, down 342.86% from ¥0.07 in the previous year[92]. - The weighted average return on net assets was -5.23%, a decrease of 7.32% compared to 2.09% in the previous year[92]. - The net cash flow from operating activities was -¥165,088,204.67, an improvement of 41.55% compared to -¥282,443,577.36 in the same period last year[92]. - The total assets at the end of the reporting period were ¥5,893,346,558.10, a decrease of 2.36% from ¥6,035,803,472.83 at the end of the previous year[92]. - The company reported a significant decrease in cash flow from financing activities, down 87.83% to ¥75,411,930.89 from ¥619,664,063.88[106]. - The company reported a net increase in cash and cash equivalents of -¥228,815,021.63, compared to an increase of ¥113,984,840.70 in the previous year[78]. Market and Competition - The decrease in revenue was primarily due to intensified competition in the domestic heparin preparation market and a reduction in demand for heparin raw materials abroad[32]. - The company is facing risks related to policy changes, industry competition, and new product development, which are detailed in the risk management section of the report[12]. - The company is facing risks related to the potential inclusion of heparin sodium injection in the national centralized procurement list, which could impact sales and market share[165]. - The market price of heparin raw materials has been on the rise, but recent trends indicate a potential decline, posing a risk of inventory impairment[168]. Product Development and R&D - The company plans to enhance its product structure and actively promote innovative drug research and development[32]. - The R&D focus includes expanding the heparin product line and developing new drugs, with increased investment planned for the coming years[49]. - The company is actively developing new products, including hyaluronic acid raw materials and related cosmetics, as well as sildenafil citrate, indicating a diversification strategy[71]. - The company is committed to balancing generic and innovative drug development to mitigate R&D risks and enhance project management[166]. - The company is advancing the Phase III clinical trial of Aibennapeptide, with data unblinding completed on June 27, 2023, and plans to submit an NDA to CDE by the end of the year[188]. Inventory and Assets - The company's total inventory balance as of June 30, 2023, is CNY 2,581,921,259, an increase from CNY 2,526,456,230 at the beginning of the period[37]. - The raw materials inventory value is CNY 16,884,497.63, with a decrease from CNY 25 at the beginning of the period[36]. - The company’s inventory at the end of the period totaled ¥55,465,029.11, reflecting a strategic buildup of resources for future sales[62]. - The company maintains a high proportion of inventory value in current assets, primarily consisting of heparin raw materials and finished goods[168]. Financial Management and Investments - The company has committed a total investment of CNY 58,335.29 million for the polysaccharide and peptide product industrialization project, with an actual investment of CNY 18,037.82 million, achieving 100% of the planned investment progress[112]. - The total investment amount for the reporting period is ¥4,000,000.00, a drastic reduction of 97.41% from ¥154,300,000.00 in the same period last year[111]. - The company has not engaged in any entrusted financial management or derivative investments during the reporting period[117][119]. - The company has postponed some fundraising investment projects due to delays in equipment arrival and construction progress, as well as changes in the domestic and international market environment[115]. Strategic Initiatives - The company has established a mature domestic and overseas marketing network, reducing dependency on a single market[48]. - The company aims to enhance its international market presence through FDA certifications for its heparin products[48]. - The company is committed to optimizing its business composition and product structure in response to market changes[32]. - The company is enhancing its capabilities across R&D, production, marketing, and management to address increasing market competition[165]. Subsidiary Performance - The company reported a loss of ¥19,054,565.99 in the biotechnology and pharmaceutical research subsidiary, with total revenue of ¥356,210,436.86[121]. - Several subsidiaries, including Changshan Jiukang and Changshan Kaijie, reported losses due to being in the R&D or construction phases without operational revenue[164]. - The company’s subsidiary in the biopharmaceutical sector reported revenue of ¥273,471,524.96, with a net profit of ¥10,740,828.66[121]. Regulatory and Compliance - The company has been recognized as a national enterprise technology center and a high-tech enterprise, enhancing its reputation and potential for innovation[71]. - 常山生化药业（江苏）有限公司在生产中严格遵守多项环境保护法律法规，确保合规运营[196].

证券代码：300255 证券简称：常山药业 公告编号：2023-40 河北常山生化药业股份有限公司 记载、误导性陈述或重大遗漏。 一、获得补助的基本情况 河北常山生化药业股份有限公司（以下简称"公司"）及子公司于 2023 年 4 月 22 日至 2023 年 8 月 18 日收到与收益相关的政府补助 191.32 万元（占公司最近 一期经审计净利润的 10.92%），公司已实际收到前述相关款项，具体情况如下： | | | | | | | 计 | 与资 | | 是 否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 获得补 | 提供补 | | 补助 | 补助依据 | 入 | 产相 | | 具 | | 序 | 助的主 | 助的主 | 补助的原 | 金额 | （政府文 | 会 | 关/ | 收到补助 | 有 | | 号 | 体 | 体 | 因或项目 | （万 | 件） | 计 | 收益 | 的时间 | 持 | | | | | | 元） | | 科 | | | | | | | | | | | 目 | 相关 | | 续 | | | ...

证券代码： 300255 证券简称：常山药业 河北常山生化药业股份有限公司投资者关系活动记录表 编号：2023-2 | --- | --- | --- | |----------------|---------------------------|----------------------------------------------------------------| | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | √ 其他 （河北辖区上市公司 | 2023 年投资者网上集体接待日活动） | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2023 年 5 月 30 日 ( | 周二) 下午 15:00~17:00 | | 地点 | | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开 | | | 上市公司接待人 | 1、财务总监王军 | | | ...

证券代码：300255 证券简称：常山药业 公告编号：2023-24 河北常山生化药业股份有限公司 关于参加河北辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，河北常山生化药业股份有限公司（以下 简称"公司"）将参加由河北证监局、河北省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年河北辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2023 年 5 月 30 日（周二）15:00-17:00。届时公司高 管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况和可持续发展 等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 河北常山生化药业股份有限公司董事会 2023 年 5 月 25 日 ...

证券代码： 300255 证券简称：常山药业 6、2018 年开始的和以 Kitov 公司合作，至今进展情况怎么， 谢谢回答。 河北常山生化药业股份有限公司投资者关系活动记录表 编号：2023-1 | 投资者关系活动 | 特定对象调研 分析师会议 □ □ | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 18 日 (周四) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长高晓东 | | 员姓名 | 2、财务总监王军 | | | 3、董事会秘书刘中英 | | | 4、独立董事曹德英 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问 ...

为使投资者能够进一步了解公司的生产经营等情况，公司定于 2023 年 5 月 18 日（星期四）15:00－17:00 在全景网举办 2022 年度业绩网上说明会，本次年 度业绩说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://rs.p5w.net）参与互动交流。 出席本次说明会的人员有：公司董事长高晓东先生、财务总监王军先生、董 事会秘书刘中英先生、独立董事曹德英先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 17 日（星期三）17:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的 问题进行回答。 证券代码：300255 证券简称：常山药业 公告编号：2023-22 河北常山生化药业股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

Financial Performance - Net profit for the period was 558,681.84 CNY, a significant decline from 28,851,938.26 CNY in the previous period, indicating a drop of approximately 98.1%[1] - Basic and diluted earnings per share were both 0.0049 CNY, down from 0.0317 CNY in the previous period, a decrease of about 84.5%[4] - Total comprehensive income attributable to the parent company was 3,861,127.43 CNY, compared to 27,986,439.91 CNY in the previous period, a decrease of about 86.1%[4] - Operating profit for the period was 5,752,668.19 CNY, down from 33,283,613.23 CNY, a decrease of approximately 82.7%[1] - The total profit for the period was 5,744,169.24 CNY, significantly lower than 33,232,129.93 CNY in the previous period, indicating a decline of about 82.7%[1] - Net profit attributable to shareholders of the listed company was ¥4,541,481.07, down 84.68% from ¥29,651,405.14 year-on-year[39] - The net profit after deducting non-recurring gains and losses was -¥5,467,837.78, a decline of 120.01% compared to ¥27,324,880.94 in the previous year[39] - Net profit attributable to the parent company decreased by 84.68% year-on-year, mainly due to reduced sales revenue and increased operating costs[58] Revenue and Costs - Total operating costs for the period were 507,965,611.18 CNY, a decrease from 542,640,735.36 CNY in the previous period, representing a reduction of approximately 6.35%[1] - Cash received from sales of goods and services was 516,943,367.04 CNY, down from 567,261,182.52 CNY, a decline of approximately 8.8%[5] - Total operating revenue for the first quarter was ¥501,924,319.12, a decrease of 12.58% compared to ¥574,179,074.10 in the same period last year[39] - The company's operating revenue decreased by 12.58% year-on-year, primarily due to a decline in the price of heparin raw materials and a drop in sales volume of low molecular weight heparin[58] - Sales expenses decreased by 34.42% compared to the same period last year, mainly due to a decrease in sales revenue[45] Cash Flow - The net cash flow from operating activities was -99,744,873.23, an improvement from -158,674,887.67 in the previous period, indicating a 37% reduction in cash outflow[8] - Cash flow from operating activities increased by 37.14% year-on-year, primarily due to a decrease in cash paid for purchasing goods and receiving services[59] - Cash flow from investing activities decreased by 32.88% year-on-year, mainly due to reduced cash payments for the purchase of fixed assets, intangible assets, and other long-term assets[60] - Cash flow from financing activities decreased by 104.61% year-on-year, primarily due to increased cash payments for debt repayment and decreased cash received from borrowings[60] Assets and Liabilities - The total assets decreased to 5,988,652,588.93 from 6,035,803,472.83, reflecting a decline of approximately 0.78%[13] - Current assets totaled 3,768,013,582.66, down from 3,897,553,391.47, indicating a decrease of about 3.32%[13] - Inventory increased slightly to 2,457,407,774.07 from 2,431,477,436.45, showing a growth of approximately 1.06%[13] - The company's long-term assets increased to 2,220,639,006.27 from 2,138,250,081.36, representing a growth of about 3.84%[13] - The short-term borrowings rose to 1,034,922,546.84 from 971,316,007.39, an increase of approximately 6.5%[13] - Total cash inflow from financing activities was 256,504,238.08, down 42% from 439,130,477.50 in the previous period[8] - The total cash outflow from financing activities was 273,066,875.93, significantly higher than 79,967,821.89 in the previous period, resulting in a net cash flow from financing activities of -16,562,637.85[8] Other Financial Metrics - The company reported a net loss from credit impairment of 1,598,914.09 CNY, contrasting with a gain of 1,408,421.45 CNY in the previous period[1] - Other comprehensive income after tax was -680,353.64 CNY, compared to -1,664,965.23 CNY in the previous period, showing an improvement[4] - Accounts receivable financing increased by 55.40% compared to the beginning of the period, mainly due to an increase in AAA-rated bills[30] - Other income increased by 221.52% year-on-year, primarily due to an increase in government subsidies received during the period[33] - Minority interests decreased by 99.02% compared to the beginning of the period, mainly due to the net loss of the controlling subsidiary during the period[32] - Minority interest loss decreased by 398.18% year-on-year, primarily due to a decrease in net profit of the controlling subsidiary[46] - Other current assets increased by 78.14% compared to the beginning of the period, mainly due to an increase in deductible input tax[43] - Accounts receivable decreased by 86.03% compared to the beginning of the period, mainly due to a reduction in non-AAA rated notes[42] - Accounts payable decreased by 72.85% compared to the beginning of the period, primarily due to a reduction in note settlement business[44]

Production Capacity and Product Development - The company is expanding its heparin raw material production capacity by 35 tons to address capacity bottlenecks and enhance net profit margins from heparin raw materials[7]. - The company is actively promoting the bulk export and international registration of non-pig heparin products[8]. - The company has developed advanced biochemical technologies that significantly improve product yield and reduce production cycles, achieving standards higher than industry norms[2]. - The company plans to expand its raw material drug production capacity and actively promote innovative drug research and development[147]. - The company is actively developing non-pig source low molecular weight heparin, with successful HALAL certification for bovine heparin sodium products in Indonesia and Malaysia[155]. - The company is advancing the clinical trials for Abenatide injection, with all subjects enrolled by January 2022, and is progressing with two anti-tumor targeted new drugs in preclinical research[154]. - The company’s research institute focuses on expanding its heparin product line, polysaccharide and peptide products, and developing anti-tumor drugs, with increased investment in R&D planned for the coming years[172]. Financial Performance - The company achieved operating revenue of CNY 2,336.23 million in 2022, a decrease of 21.29% compared to the previous year[129]. - The net profit attributable to shareholders was CNY 17.51 million, representing a decline of 92.50% year-on-year[147]. - Domestic sales accounted for 72.94% of total revenue, while international sales contributed 27.06%, with international sales decreasing by 37.49%[129]. - The gross profit margin for the biopharmaceutical sector was 45.71%, down 13.44% from the previous year[130]. - Revenue from low molecular weight heparin preparations dropped by 27.55% to $1,205,645,412.90, representing 51.61% of total revenue[187]. - Revenue from ordinary heparin raw materials was $596,724,641.10, accounting for 25.54% of total revenue, down 13.78%[187]. - The revenue from ordinary heparin preparations surged by 196.24% to $35,517,662.19, making up 1.52% of total revenue[187]. - Other revenue sources contributed $63,319,199.97, which is 2.71% of total revenue, down 19.86% year-over-year[187]. Corporate Governance and Internal Control - The company maintains a strong commitment to corporate governance, ensuring compliance with relevant laws and regulations[13]. - The company emphasizes talent development and has established a drug research institute to ensure continuous technological innovation[4]. - The company is optimizing its internal control system to mitigate management risks and enhance operational efficiency[10]. - The independent directors provided impartial opinions on the annual profit distribution plan and external guarantees during the reporting period[35]. - The company has maintained a risk-oriented approach in its internal control supervision activities, with no significant issues reported during the period[37]. - The company has not encountered any significant internal control deficiencies in financial reporting during the reporting period[96]. - The company has a complete mechanism for determining the remuneration of directors and senior management based on performance and capability assessments[63]. Environmental Compliance - The company has completed environmental impact assessments for multiple projects, including a series of polysaccharide and protein peptide products[79]. - The company has obtained pollution discharge permits valid until 2026 for its subsidiaries, ensuring compliance with environmental regulations[81]. - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring results meeting the relevant discharge standards[91]. - The wastewater treatment facility processed a total of 42,410.52 tons of wastewater in 2022, with no instances of exceeding discharge standards[87]. - The company’s air pollution control systems, including a chemical deodorization system and a biological deodorization system, operated normally throughout the year, meeting emission standards[111]. - The company has invested approximately CNY 1 million in environmental governance and protection in 2022[119]. - The company has a compensation limit of CNY 3 million for its environmental pollution liability insurance, effective from July 23, 2022, to July 22, 2023[122]. - The company has not reported any penalties or rectification measures during the reporting period[195]. Market Strategy and Sales - The company has established a mature domestic and international marketing network, reducing dependency on any single market[4]. - The company is adjusting its product and customer structure to adapt to market changes, aiming for higher sales revenue[7]. - The company has a complete and independent production and sales system, allowing for autonomous decision-making and contract signing[50]. - The company has continuously improved its internal control system to adapt to changing external environments and internal management requirements[44]. - The company has established a unique competitive advantage in the industry through 20 years of efforts in supply chain management, quality control, international market layout, and independent innovation, ensuring sustainable growth in performance[168]. Shareholder Communication and Dividends - The company proposed a cash dividend of RMB 0.26 per 10 shares (including tax) based on the total share capital after deducting shares in the repurchase account[40]. - The company has not engaged in any investor communication activities during the reporting period[11]. - The company’s profit distribution plan complies with relevant regulations and the company’s articles of association[41]. - The company has a clear and transparent cash dividend policy that aligns with its articles of association and shareholder resolutions[71]. - The company has not proposed a cash dividend distribution plan despite having positive distributable profits for the parent company during the reporting period[72]. Legal Matters - The company has received four lawsuits related to false securities statements in 2022, with one case still under trial, while two claims were dismissed[185]. - There were no related party transactions involving asset or equity acquisitions or sales during the reporting period[196]. - The company did not engage in any related party debt or equity transactions during the reporting period[198]. - There were no significant contracts that contributed to over 10% of the total profit during the reporting period[190].